Analysts See Pipeline Catalysts Driving Teva Pharmaceutical Industries Limited (TEVA)'s 2026 Growth Despite Revenue Headwinds [Yahoo! Finance]
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Yahoo! Finance
its price target on Teva Pharma (NYSE:TEVA) to $38 from $36 while keeping a Buy rating, following Q4 2025 results that included a $500 million milestone payment. Although normalized revenue missed estimates by about 1%, Truist sees Teva's growth story as intact, pointing to pipeline catalysts in 2026 such as a potential FDA decision on Olanzapine LAI, which could unlock a $3B sales opportunity. The firm also expects biosimilars to support the generics business despite headwinds from gRevlimid sales and tougher Austedo comparisons, noting Teva's PEG ratio of 0.3 suggests attractive value relative to growth. The same day Teva Pharmaceutical Industries reported strong Q4 2025 results, beating expectations with EPS of $0.96 versus $0.65 forecast and revenue of $4.71 billion against $4.33 billion expected, aided by a $500 million milestone payment from Sanofi. Despite this, shares slipped as Teva projected lower 2026 revenue of $16.4–$16.8 billion and adjusted EPS of $2.57–$2.77, refle
Show less
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- Jim Cramer Highlights Teva Pharmaceutical's Growth Under CEO Richard Francis [Yahoo! Finance]Yahoo! Finance
- Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TEVA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">WMarketBeat
- Does Teva's Return To Profitability And Branded-Drug Shift Reshape The Bull Case For TEVA? [Yahoo! Finance]Yahoo! Finance
- Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Barclays PLC from $35.00 to $38.00. They now have an "overweight" rating on the stock.MarketBeat
- Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Truist Financial Corporation from $36.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
TEVA
Earnings
- 1/28/26 - Beat
TEVA
Sec Filings
- 1/29/26 - Form 4
- 1/29/26 - Form 4
- 1/29/26 - Form 4
- TEVA's page on the SEC website